Find links to news and information about Cala Health, our history, and Cala Trio in our newsroom.
In The News
Cala Cites Positive Data in Trio Tremor Trial
Bioelectronic company Cala Health released positive data from its ongoing PROSPECT trial demonstrating that a majority of patients using its FDA-cleared Cala Trio device reported a reduction in hand tremors.
Cala Health aims to restore functionality to essential tremor patients with wearables
For Kate Rosenbluth, founder and chief scientific officer of Cala Health, and Renee Ryan, its CEO, the painting is a reminder of why they do their work every day: to restore functionality — and even bring back the joy of life — for the estimated 7 million people in the U.S. living with the condition.
Wearables are a hot topic in medtech circles today. But are they really medtech? Cala Health’s Trio device for treating essential tremors underscores the challenges and opportunities that wearables represent when compared to traditional medical devices.
It looks like a smartwatch, but this new device is helping people with tremors
People who live with tremors know it can impact every part of your life. Essential tremor is a nervous system disorder that causes involuntary shaking. It can be hard to write legibly, and even eat or drink without spilling.
Individualized, Non-invasive therapy for essential tremor- An interview with Kate Rosenbluth of Cala Health
When I was an Innovation Fellow, doing needs finding with my team, I met a man whose hands shook so badly that he could no longer write a letter to his wife or drink a coffee with a friend. He had a severe form of a debilitating disorder called essential tremor.
Record Clinical Trial Enrollment Made Possible by IETF and Their Members
Patient recruitment is usually the biggest challenge in conducting clinical trials. Thanks to the International Essential Tremor Foundation and their members, CalaHealth recently enrolled the largest therapeutic essential tremor study in record time.
Essential Tremor Symptoms, Severity Improved With Cala Trio Neuromodulation Device
Results of the landmark PROSPECT trial of the Cala Trio, a wrist-worn wearable neuromodulation device for essential tremor (ET), suggest that the device is safe and effective for the reduction of hand tremor in individuals with ET.
Electricity as Medicine: Lux Capital's Josh Wolfe and Cala Health CEO Renee Ryan
Lux Capital Managing Partner and Co-Founder Josh Wolfe visits the headquarters of Lux portfolio company Cala Health in Burlingame, California and has a conversation with CEO Renee Ryan. You’ll get an inside look at how Cala is empowering people with chronic disease.
Cala Health named A GOLD WINNER of the 2020 Edison Awards
Cala Trio therapy took the GOLD award for Diagnostics & Disease Treatment in the Medical Device/Dental category. Among the nomination entries comprising the best products, services, and businesses in innovation for the year 2020, Cala Trio was chosen as a winner by a panel of over 3,000 leading business executives from around the world.
Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™
Based on its recent analysis of the North American essential tremor (ET) treatment market, Frost & Sullivan recognizes Cala Health, Inc. with the 2019 North American Technology Innovation Award for its Cala Trio™, a prescription-only, wrist-worn device.
We highlight 2020’s emerging trends to watch and high-momentum startups with world-changing potential. The past few decades have seen unprecedented levels of innovation, especially in what Peter Thiel calls the world of “bits,” or software, internet, and mobile technology.